CA3043132A1 - Benzodiazolium compounds as enac inhibitors - Google Patents

Benzodiazolium compounds as enac inhibitors Download PDF

Info

Publication number
CA3043132A1
CA3043132A1 CA3043132A CA3043132A CA3043132A1 CA 3043132 A1 CA3043132 A1 CA 3043132A1 CA 3043132 A CA3043132 A CA 3043132A CA 3043132 A CA3043132 A CA 3043132A CA 3043132 A1 CA3043132 A1 CA 3043132A1
Authority
CA
Canada
Prior art keywords
amino
methyl
benzodiazol
ium
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3043132A
Other languages
English (en)
French (fr)
Inventor
Clive Mccarthy
Jonathan David HARGRAVE
Duncan Alexander HAY
Thomas Beauregard SCHOFIELD
Naomi WENT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enterprise Therapeutics Ltd
Original Assignee
Enterprise Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterprise Therapeutics Ltd filed Critical Enterprise Therapeutics Ltd
Publication of CA3043132A1 publication Critical patent/CA3043132A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3043132A 2016-11-22 2017-11-22 Benzodiazolium compounds as enac inhibitors Pending CA3043132A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1619694.1 2016-11-22
GBGB1619694.1A GB201619694D0 (en) 2016-11-22 2016-11-22 Compounds
PCT/GB2017/053499 WO2018096325A1 (en) 2016-11-22 2017-11-22 Benzodiazolium compounds as enac inhibitors

Publications (1)

Publication Number Publication Date
CA3043132A1 true CA3043132A1 (en) 2018-05-31

Family

ID=57993838

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043132A Pending CA3043132A1 (en) 2016-11-22 2017-11-22 Benzodiazolium compounds as enac inhibitors

Country Status (20)

Country Link
US (4) US10941149B2 (enExample)
EP (1) EP3544981B1 (enExample)
JP (1) JP6980014B2 (enExample)
KR (1) KR102517273B1 (enExample)
CN (1) CN110214141B (enExample)
AU (1) AU2017364308B2 (enExample)
CA (1) CA3043132A1 (enExample)
DK (1) DK3544981T3 (enExample)
EA (1) EA039607B1 (enExample)
ES (1) ES2890226T3 (enExample)
GB (1) GB201619694D0 (enExample)
HU (1) HUE055692T2 (enExample)
IL (1) IL266745B (enExample)
MA (1) MA46878A (enExample)
MX (1) MX389496B (enExample)
PL (1) PL3544981T3 (enExample)
PT (1) PT3544981T (enExample)
TW (1) TWI756305B (enExample)
WO (1) WO2018096325A1 (enExample)
ZA (1) ZA201902710B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) * 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
PH12021553110A1 (en) 2019-06-12 2022-08-01 Tmem16A Ltd Compounds for treating respiratory disease
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
GB201910608D0 (en) 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
AR124316A1 (es) * 2020-12-11 2023-03-15 Tmem16A Ltd Compuestos para tratar una enfermedad respiratoria
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
GB202406247D0 (en) 2024-05-03 2024-06-19 Enterprise Therapeutics Ltd Compounds and pharmaceutical compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
KR20060115348A (ko) 2003-08-18 2006-11-08 패리온 사이언스 인코퍼레이티드 지방족 피라지노일구아니딘 나트륨 채널 차단제
AU2004264441A1 (en) 2003-08-18 2005-02-24 Parion Sciences, Inc. Cyclic pyrazinoylguanidine sodium channel blockers
SI1663235T1 (sl) 2003-08-18 2013-12-31 Parion Sciences, Inc. Zaščiteni pirazinoilgvanidinski blokatorji natrijevega kanala
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
KR20060115396A (ko) 2003-10-28 2006-11-08 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서 유용한 벤즈이미다졸
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
MX2007011234A (es) * 2005-03-14 2007-11-12 Transtech Pharma Inc Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8288391B2 (en) 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
KR20100005730A (ko) 2007-05-07 2010-01-15 노파르티스 아게 유기 화합물
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
AU2009246799B2 (en) 2008-02-26 2014-02-27 Parion Sciences, Inc. Poly aromatic pyrazinoylguanidine sodium channel blockers
JP2011520831A (ja) 2008-05-13 2011-07-21 ノバルティス アーゲー ３，５−ジアミノ−６−クロロ−ピラジン−２−カルボン酸誘導体および気道疾患処置用上皮性ナトリウムチャネルブロッカーとしてのその使用
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) * 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TW201204353A (en) * 2010-06-08 2012-02-01 Vertex Pharma Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
HRP20171614T1 (hr) 2011-11-02 2017-12-01 Boehringer Ingelheim International Gmbh Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
CA2872029A1 (en) 2012-05-29 2013-12-05 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
EP2897940B1 (en) 2012-09-24 2019-05-01 Boehringer Ingelheim International GmbH Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
PE20151054A1 (es) 2012-12-17 2015-08-07 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
JP6353032B2 (ja) 2013-04-30 2018-07-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジアミノピラジン化合物、前記化合物を含有する医薬、その使用、およびその調製方法
CA2915633A1 (en) 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
EP3019492B1 (en) 2013-07-08 2017-09-06 Boehringer Ingelheim International GmbH Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
WO2015007516A1 (en) * 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel 5-substituted benzimidazolium compounds
WO2015007517A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel tetra- and pentasubstituted benzimidazolium compounds
JP6461134B2 (ja) 2013-07-15 2019-01-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ベンゾイミダゾリウム化合物
JP6449880B2 (ja) 2013-08-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピラジンアミド化合物
JP6667537B2 (ja) 2015-01-12 2020-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療に有用な四置換及び五置換ベンズイミダゾリウム化合物
US9932324B2 (en) 2015-01-12 2018-04-03 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
JP6671378B2 (ja) * 2015-01-12 2020-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療に有用な置換ベンズイミダゾリウム化合物
JP6847838B2 (ja) 2015-01-12 2021-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 上皮ナトリウムチャネル阻害剤としての２−（ピラジン−２−イルカルボニルアミノメチル）ベンズイミダゾリウム化合物
KR20180040699A (ko) 2015-08-20 2018-04-20 베링거 인겔하임 인터내셔날 게엠베하 신규한 어닐링된 벤즈아미드
SI3298022T1 (sl) 2015-08-20 2019-08-30 Boehringer Ingelheim International Gmbh Novi anelirani fenoksiacetamidi
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
EP3544981A1 (en) 2019-10-02
ZA201902710B (en) 2021-10-27
US11739094B2 (en) 2023-08-29
JP2019535747A (ja) 2019-12-12
GB201619694D0 (en) 2017-01-04
TW201833111A (zh) 2018-09-16
WO2018096325A1 (en) 2018-05-31
EA039607B1 (ru) 2022-02-16
PT3544981T (pt) 2021-09-23
AU2017364308B2 (en) 2021-03-11
CN110214141A (zh) 2019-09-06
CN110214141B (zh) 2022-05-31
DK3544981T3 (da) 2021-09-20
IL266745A (en) 2019-07-31
US12371436B2 (en) 2025-07-29
HUE055692T2 (hu) 2021-12-28
BR112019009864A2 (pt) 2019-08-27
AU2017364308A1 (en) 2019-05-23
MA46878A (fr) 2019-10-02
MX2019005934A (es) 2019-11-12
US10941149B2 (en) 2021-03-09
US20210147432A1 (en) 2021-05-20
IL266745B (en) 2021-12-01
ES2890226T3 (es) 2022-01-18
MX389496B (es) 2025-03-20
EP3544981B1 (en) 2021-06-23
KR20190084076A (ko) 2019-07-15
KR102517273B1 (ko) 2023-04-03
US20250304590A1 (en) 2025-10-02
JP6980014B2 (ja) 2021-12-15
EA201991253A1 (ru) 2019-11-29
NZ753048A (en) 2024-09-27
US20190315757A1 (en) 2019-10-17
PL3544981T3 (pl) 2021-12-20
US20240067653A1 (en) 2024-02-29
TWI756305B (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
US12371436B2 (en) Substituted benzodiazoliums as ENaC inhibitors
EP3794002B1 (en) Compounds
ES2398428T3 (es) Derivados de triazol útiles para el tratamiento de enfermedades
US10759785B2 (en) Compounds
PT2702061E (pt) Derivados de pirrolotriazinona como inibidores de pi3k
US20110028447A1 (en) Indazole derivatives
MX2015004327A (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
EP3697788B1 (en) Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1h-1,3-benzodiazol-3-ium derivatives as enac inhibitors for treating respiratory diseases
US12552770B2 (en) Compounds for treating respiratory disease
HK40014276A (en) Benzodiazolium compounds as enac inhibitors
HK40014276B (en) Benzodiazolium compounds as enac inhibitors
BR112019009864B1 (pt) Compostos de benzodiazolínio, composição farmacêutica e produto compreendendo os referidos compostos, seus processos de fabricação e uso

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220728

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240722

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241115

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241115

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241220

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250123

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250123

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251113

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251113

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260106